In a field craving innovation, Bone Health Technologies stands as a trailblazer. Their latest marvel, Osteoboost, stole the show at Endo 2023, the annual meeting of the Endocrine Society. The presented data exhibited Osteoboost’s prowess in fighting the age-old nemesis of postmenopausal women: low bone mass.
The study, double-blinded and sham-controlled, scrutinized the effects of Osteoboost on 126 postmenopausal women with low bone mass. The results? A staggering 82% reduction in the rate of bone strength loss and an 85% reduction in the loss of bone density.
Laura Bilek, Ph.D., lauded Osteoboost’s potential in understanding new mechanisms for reducing bone loss post-menopause. Laura Yecies, CEO of Bone Health Technologies, affirmed that Osteoboost is the first non-pharmacological intervention showing such efficacy.
With Osteoboost’s user-friendly design and targeted vibration technology, the future of bone health treatment appears promising.